Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors Academic Article uri icon

Overview

MeSH Major

  • Cisplatin
  • Dacarbazine
  • Drug Resistance, Neoplasm
  • Germinoma

abstract

  • Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

publication date

  • April 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1023/B:DRUG.0000011794.21608.59

PubMed ID

  • 14739666

Additional Document Info

start page

  • 177

end page

  • 9

volume

  • 22

number

  • 2